Remdesivir

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Remdesivir is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Remdesivir is an investigational agent (not FDA approved) that has been authorized for use (EUA) in the U.S. by FDA under an Emergency Use Authorization (EUA) for treatment of suspected or laboratory-confirmed SARS-Co-2 infection (COVID-19) in adults and children hospitalized with severe diseases.
  • Severe disease is defined as:
    • Patients with SpO2 ≤ 94% on room air, OR
    • Requiring supplemental oxygen, OR
    • Requiring mechanical ventilation, OR
    • Requiring extracorporeal membrane oxygenation (ECMO)

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Remdesivir is an investigational agent (not FDA approved) that has been authorized for use (EUA) in the U.S. by FDA under an Emergency Use Authorization (EUA) for treatment of suspected or laboratory-confirmed SARS-Co-2 infection (COVID-19) in adults and children hospitalized with severe diseases.
  • Severe disease is defined as:
    • Patients with SpO2 ≤ 94% on room air, OR
    • Requiring supplemental oxygen, OR
    • Requiring mechanical ventilation, OR
    • Requiring extracorporeal membrane oxygenation (ECMO)

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: October 2, 2020